MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.91 6.25

Resumen

Variación precio

24h

Actual

Mínimo

3.87

Máximo

3.92

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+8.42% upside

Dividendos

By Dow Jones

Próximas Ganancias

17 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

367M

1.4B

Apertura anterior

-2.34

Cierre anterior

3.91

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 ene 2026, 23:29 UTC

Acciones populares

Stocks to Watch: Atossa Therapeutics, Union Pacific

17 ene 2026, 15:06 UTC

Adquisiciones, fusiones, absorciones

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17 ene 2026, 10:30 UTC

Ganancias

Supersize CEO Pay Packages Aren't Paying Off for Shareholders -- WSJ

17 ene 2026, 03:10 UTC

Adquisiciones, fusiones, absorciones

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16 ene 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 ene 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 ene 2026, 21:48 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 ene 2026, 21:41 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 ene 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 ene 2026, 20:44 UTC

Ganancias

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 ene 2026, 20:42 UTC

Charlas de Mercado

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 ene 2026, 20:28 UTC

Charlas de Mercado

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 ene 2026, 19:12 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 ene 2026, 18:53 UTC

Charlas de Mercado

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 ene 2026, 18:41 UTC

Charlas de Mercado

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 ene 2026, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 ene 2026, 17:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

8.42% repunte

Estimación a 12 meses

Media 4.25 USD  8.42%

Máximo 4.5 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat